 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12345678910111213...235236» |
- | Retrospective data, Journal: KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. (Pubmed Central) - Jan 12, 2025
KRAS G12R was associated with more favorable patient outcomes, and FOLFIRINOX was associated with better patient outcomes than gemcitabine-based therapies. These findings highlight the need for more effective systemic therapies for these groups of patients.
- |||| Krazati (adagrasib) / BMS, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (clinicaltrials.gov) - Jan 10, 2025
P3, N=461, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
These findings highlight the need for more effective systemic therapies for these groups of patients. Trial primary completion date: Feb 2025 --> Jan 2026
- || onvansertib (PCM-075) / Cardiff Oncology
Trial completion, Trial completion date, Trial primary completion date: ONSEMBLE: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation (clinicaltrials.gov) - Jan 10, 2025
P2, N=23, Completed, Sponsor: Cardiff Oncology
Trial primary completion date: Feb 2025 --> Jan 2026 Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Dec 2024 | Trial primary completion date: Nov 2025 --> Dec 2024
- | erlotinib / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: PANGEA: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (clinicaltrials.gov) - Jan 10, 2025
P1/2, N=104, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Dec 2024 | Trial primary completion date: Nov 2025 --> Dec 2024 Trial completion date: Aug 2026 --> Aug 2027 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Aug 2026 --> Aug 2027
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Gold nanoparticles decorated FOLFIRINOX loaded liposomes for synergistic therapy of pancreatic cancer. (Pubmed Central) - Jan 9, 2025
Combination therapy has a higher therapeutic efficacy (70.45?%) when compared to chemotherapy and photothermal therapy used separately. The study's results show the potential of combination therapies to improve therapeutic outcomes, providing a promising path for future research and clinical application.
- | Journal: Reverse engineering of Onivyde (Pubmed Central) - Jan 9, 2025
The study's results show the potential of combination therapies to improve therapeutic outcomes, providing a promising path for future research and clinical application. Onivyde
- | Journal, PD(L)-1 Biomarker, IO biomarker, Immune cell: Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells. (Pubmed Central) - Jan 9, 2025
Our data show that immune cell distribution after systemic chemotherapy changes in peripheral blood. Interestingly, in peritoneal fluid only the inhibitory Treg population decreased and local T
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Trial completion: AVETRIC: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jan 9, 2025
P2, N=62, Completed, Sponsor: Gruppo Oncologico del Nord-Ovest
Interestingly, in peritoneal fluid only the inhibitory Treg population decreased and local T Active, not recruiting --> Completed
- ||| P3 data, Journal, Metastases: Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial. (Pubmed Central) - Jan 8, 2025
P3
Administering trilaciclib prior to FOLFOXIRI/bevacizumab protected the neutrophil lineage from the effects of chemotherapy-induced myelosuppression. However, antitumor efficacy endpoints favored placebo.
- || lunresertib (RP-6306) / Repare Therap
Trial completion date, Trial primary completion date: RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov) - Jan 8, 2025
P2, N=78, Recruiting, Sponsor: Canadian Cancer Trials Group
However, antitumor efficacy endpoints favored placebo. Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- Avastin (bevacizumab) / Roche
Preferred treatment regimens for rare genitourinary (GU) malignancies. (Level 1, West Hall; Poster Bd #: F7) - Jan 7, 2025 - Abstract #ASCOGU2025ASCO_GU_253;
These results are being used to inform the design of a first-line clinical trial to evaluate the most efficacious therapy for these rare GU malignancies. ITP - ifosfamide, paclitaxel, and cisplatin; EP
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
Observational data, Journal: Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort. (Pubmed Central) - Jan 6, 2025
BTC patients were predominantly treated according to international recommendations. The obtained demographic, tumor, and molecular data were consistent with existing literature.
- || 5-fluorouracil / Generic mfg.
Clinical, Journal, Metastases: Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer. (Pubmed Central) - Jan 6, 2025
The obtained demographic, tumor, and molecular data were consistent with existing literature. Our results suggest a low level of FOLFOXIRI or FOLFIRINOX +/- BV exposure in first-line mCRC is associated with a significant trend on PFS and OS.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Low-Risk Gestational Trophoblastic Neoplasia: Insights From A Tertiary Care Institute In India (Poster area) - Jan 4, 2025 - Abstract #ESGO2025ESGO_786;
All three patients who failed primary MTX therapy were subsequently treated with multiagent chemotherapy and achieved complete remission (CR). Overall survival (OS) and cure rates for all patients with low-risk GTN were 100%.Conclusion The MTX regimen was remarkably effective in treating women with low-risk GTN, achieving a complete response (CR) rate of 91.4% without encountering severe adverse effects.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
"Oral L-Methyl Folate" May Substitute "Parenteral Folinic Acid" In The Methotrexate-Containing Chemotherapy Protocols In Low-Resource Countries: An Evidence-Based Review. (Poster area) - Jan 4, 2025 - Abstract #ESGO2025ESGO_269;
The high-risk GTN group is treated with combination regimen of etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine (EMA/CO)...The absolute bioavailability of oral levoleucovorin tablets was not significantly different from that of parenteral leucovorin...The authors reported that terminal elimination half-life, apparent volume of distribution, and clearance of total folate were not significantly different among the three treatments Conclusion According to the abovementioned data; the centers of low-resource countries may use oral methotrexate antidotes among methotrexate-containing chemotherapy protocols in different types of cancers being equivalent in efficacy and safety, more convenient, and available. A large randomized-controlled study is recommended to investigate the efficacy and safety of oral L-methyl folate as an alternative to injectable leucoverin in methotrexate-containing chemotherapy protocols.
- | Fruzaqla (fruquintinib) / Takeda
Enrollment open, Checkpoint inhibition: FOLFRUS-001: Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 4, 2025
P2, N=36, Recruiting, Sponsor: Sun Yat-sen University
A large randomized-controlled study is recommended to investigate the efficacy and safety of oral L-methyl folate as an alternative to injectable leucoverin in methotrexate-containing chemotherapy protocols. Not yet recruiting --> Recruiting
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: NET-02: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (clinicaltrials.gov) - Jan 4, 2025
P2, N=58, Completed, Sponsor: The Christie NHS Foundation Trust
Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Nov 2024 | Trial primary completion date: Dec 2023 --> Nov 2024 | Active, not recruiting --> Completed | N=102 --> 58
- ||||||| Hanbeitai (bevacizumab biosimilar) / Fosun Pharma, Eurofarma
Trial completion: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC (clinicaltrials.gov) - Jan 3, 2025
P3, N=677, Completed, Sponsor: Shanghai Henlius Biotech
Trial completion date: Dec 2023 --> Nov 2024 | Trial primary completion date: Dec 2023 --> Nov 2024 | Active, not recruiting --> Completed | N=102 --> 58 Active, not recruiting --> Completed
- |||| Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Trial primary completion date: DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov) - Jan 3, 2025
P3, N=560, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Nov 2024 --> Nov 2026
- || Jemperli (dostarlimab-gxly) / GSK
New P2 trial: DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 with MFOLFIRINOX in PAncreatic Cancer (clinicaltrials.gov) - Jan 3, 2025
P2, N=35, Not yet recruiting, Sponsor: Hopital Foch
- | oxaliplatin / Generic mfg., gemcitabine / Generic mfg.
Journal, HEOR, Cost-effectiveness: Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis. (Pubmed Central) - Dec 30, 2024
The ICERs predicted by sensitivity analysis were not significantly affected by cost variations related to the management of Grade 3-4 AEs, the diagnostics used, or hospitalization expenditures. In a Chinese healthcare context, modified gemcitabine coupled with oxaliplatin (mGEMOX) is not a cost-effective treatment option for unresectable GBC.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: The Clinical Characteristics of a Stage II Colorectal Cancer T4 Tumor: A Ten-Year Single-Center Research Report. (Pubmed Central) - Dec 27, 2024
Based on our data, patients diagnosed with pathologic T4aN0M0 CRC appeared to experience a trend toward better 10-year OS when compared to those with T4bN0M0 disease, but this trend lacks statistical significance. Patients with locally advanced Stage II colon cancer clearly benefited from adjuvant chemotherapy therapy; therefore, FOLFOX may not necessarily be required.
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Dec 27, 2024
P2, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Patients with locally advanced Stage II colon cancer clearly benefited from adjuvant chemotherapy therapy; therefore, FOLFOX may not necessarily be required. Trial completion date: Sep 2024 --> Nov 2025
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. (Pubmed Central) - Dec 26, 2024
Progressive sarcopenic deterioration after four cycles of chemotherapy was associated with poor survival outcomes in patients with BR or LAPC after FOLFIRINOX. We also investigated the optimal clinical setting for the early application LRTs using the ?SMI and post-chemotherapy CA 19-9.
- |||| Zejula (niraparib) / GSK, J&J, Yervoy (ipilimumab) / BMS
New P2 trial: ParpVax2: Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy (clinicaltrials.gov) - Dec 26, 2024
P2, N=68, Not yet recruiting, Sponsor: Abramson Cancer Center at Penn Medicine
- ||| Journal, Adverse events, Metastases: The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Dec 24, 2024
We examined 3 cohorts receiving mPDAC treatment: FOLFIRINOX (FFX) (oxaliplatin, irinotecan, leucovorin, 5-FU bolus and infusion); modified FFX, (5-FU infusion only); and gemcitabine/nab-paclitaxel (gem/abrax)...Patients receiving gem/abrax were older and had higher baseline Charlson Comorbidity Index scores; however, other factors may be important in driving cost differences. Irrespective of drug cost, chemotherapy leading to a significant increase in AEs is associated with higher TCOC.
- || trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Clinical, Retrospective data, Review, Journal, Metastases: Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT. (Pubmed Central) - Dec 23, 2024
For RAS-mutant populations, FOLFIRI + Bevacizumab + Panitumumab is recommended. However, the therapeutic effect may be affected by the patient's physiological state, and clinicians should apply it based on actual conditions.
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Journal: Prognostic value of radiologic and pathological response in colorectal cancer liver metastases upon systemic induction treatment: subgroup analysis of the CAIRO5 trial. (Pubmed Central) - Dec 22, 2024
Pathological response was associated with early recurrence but is only available post-operatively. Hence, novel preoperative parameters are warranted to predict early recurrence and prevent potentially futile liver surgery.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
P2 data, Journal, Metastases: Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. (Pubmed Central) - Dec 22, 2024
P2
In older adults, induction with six cycles of FOLFIRI-A plus maintenance with 5-FU/LV-A was non-inferior to FOLFIRI-A until progression. Severe asthenia, SAEs, and treatment-related SAEs were reduced with 5-FU/LV-A maintenance.
- | leucovorin calcium / Generic mfg.
Journal: Folinic acid as a treatment for autism in children: A within-subjects open-label study on safety and efficacy. (Pubmed Central) - Dec 20, 2024
There were also trends towards gains in communication scores and overall Clinical Global Impression scores. Folinic acid is a safe and feasible potential treatment for autism, and results from this pilot justify the need for a larger placebo-controlled trial.
- | Journal, Metastases: The impact of intensified staging and combined therapies in locally advanced pancreatic cancer: a secondary analysis of prospective studies. (Pubmed Central) - Dec 20, 2024
The use of comprehensive pretreatment staging, including laparoscopy and 18F-FDG-PET/CT scan, is an effective approach in identifying occult metastatic disease in LAPC patients. Our findings offer valuable insights into accurate staging and treatment efficacy, providing evidence-based support for optimal management strategies in LAPC patients.
- | oxaliplatin / Generic mfg.
Enrollment closed: 2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) - Dec 20, 2024
P2, N=60, Active, not recruiting, Sponsor: Emory University
Our findings offer valuable insights into accurate staging and treatment efficacy, providing evidence-based support for optimal management strategies in LAPC patients. Recruiting --> Active, not recruiting
- | Journal: Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial. (Pubmed Central) - Dec 18, 2024
P3
While our study showed no significant difference in three-year RFS, adjuvant chemotherapy intensification with HAI-FUDR is feasible and may offer early benefits in RFS and long-term OS. Nonetheless, a larger sample size is needed for validation and identifying which patient subgroup might benefit from this regimen.
- | Journal: Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands. (Pubmed Central) - Dec 18, 2024
Establishing (inter)national guidelines on provisional treatment adjustment pending publication is crucial to reduce variation in access. Moreover, rapid publication of final trial results is imperative to reduce variation in practice and ensure fair patient treatment.
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Dec 18, 2024
P1, N=188, Recruiting, Sponsor: Amgen
Moreover, rapid publication of final trial results is imperative to reduce variation in practice and ensure fair patient treatment. Trial completion date: Apr 2028 --> Feb 2029 | Trial primary completion date: May 2026 --> Feb 2027
- ||| telisotuzumab adizutecan (ABBV-400) / AbbVie, budigalimab (ABBV-181) / AbbVie
Enrollment open, Adverse events: AndroMETa-GEA: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (clinicaltrials.gov) - Dec 18, 2024
P2, N=180, Recruiting, Sponsor: AbbVie
Trial completion date: Apr 2028 --> Feb 2029 | Trial primary completion date: May 2026 --> Feb 2027 Not yet recruiting --> Recruiting
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: HAICI: Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=10, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- || Opdivo (nivolumab) / BMS, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Trial completion date, Trial primary completion date: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=34, Completed, Sponsor: University of Michigan Rogel Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: May 2025 --> Nov 2024 | Trial primary completion date: May 2025 --> Nov 2024
- | FOG-001 / FogPharma
Enrollment change: FOG-001-101: FOG-001 in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=480, Recruiting, Sponsor: Parabilis Medicines, Inc.
Active, not recruiting --> Completed | Trial completion date: May 2025 --> Nov 2024 | Trial primary completion date: May 2025 --> Nov 2024 N=245 --> 480
- | certepetide (LSTA1) / Lisata Therap, Vectibix (panitumumab) / Amgen
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=50, Active, not recruiting, Sponsor: Anup Kasi
N=245 --> 480 Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
- ||| Enrollment open: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Dec 18, 2024
P1, N=542, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025 Active, not recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Journal, IO biomarker: Qualitative Transcriptional Signature for Predicting the Pathological Response of Colorectal Cancer to FOLFIRI Therapy. (Pubmed Central) - Dec 17, 2024
FOLFIRI (5-FU, leucovorin, irinotecan) is the first-line chemotherapy for metastatic colorectal cancer (mCRC), but response rates are under 50%...In conclusion, the REO-based signature effectively identifies mCRC patients likely to benefit from FOLFIRI. Furthermore, these signature genes may play a crucial role in the chemotherapy.
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAFV600E-mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial. (Level 1, West Hall; Poster Bd #: M24) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_972;
P2
Clinical Trial Registration Number: NCT06603376. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer 9NRG-GI004/SWOG-S1610). (Level 1, West Hall; Poster Bd #: M19) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_967;
P3
Clinical Trial Registration Number: NCT02997228. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- telisotuzumab adizutecan (ABBV-400) / AbbVie
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer. (Level 1, West Hall; Poster Bd #: M16) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_964;
P2
Clinical Trial Registration Number: NCT06107413. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C (Level 1, West Hall; Poster Bd #: N8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_961;
P3
Clinical Trial Registration Number: NCT06252649. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche
Liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study. (Level 1, West Hall; Poster Bd #: H7) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_875;
P2
Clinical Trial Registration Number: NCT06184698. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Kaitanni (cadonilimab) / Akesobio
Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT). (Level 1, West Hall; Poster Bd #: H22) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_869;
P2
Clinical Trial Registration Number: NCT05792735. The abstract will be released to the public on January 25, 2025 at 3:00 PM UTC
- QL1203 / Qilu Pharma
QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial. (Level 1, West Hall; Poster Bd #: H2) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_866;
P3
Clinical Trial Registration Number: NCT04233151. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: A single-arm phase II trial. (Level 1, West Hall; Poster Bd #: H13) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_859;
P2
Clinical Trial Registration Number: NCT05018182. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC